Our finding that P-SiaFNEtoc treatment downregulates the G2M checkpoint hallmark pathway, increases expression of p27/Kip1 and inhibits VEGF and DKK-1 proteins, suggests that sialylation inhibition targets key proteins critical to prostate cancer disease progression, and has important and wide-ranging implications for the treatment of prostate cancer patients. The gene discussed is CDKN1B; the disease is prostate cancer.